HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+metastatic breast cancer

被引：0
|
作者：
Hamilton, Erika P.
Martin, Miguel
O'Sullivan, Ciara Catherine
Curigliano, Giuseppe
Sohn, Joohyuk
Tsurutani, Junji
Tryfonidis, Konstantinos
Santarpia, Libero
Yang, Shan
Dieras, Veronique
机构：
[1] Tennessee Oncol, Sarah Cannon Res Inst, Nashiville, TN USA
[2] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[3] Mayo Clin, Rochester, MN USA
[4] Univ Milan, European Inst Oncol, IRCCS, Milan, Italy
[5] Yonsei Canc Ctr, Seoul, South Korea
[6] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[7] Merck & Co Inc, Rahway, NJ 07065 USA
[8] Seagen Inc, Bothell, WA USA
[9] Ctr Eugene Marquis, Rennes, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1115
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [32] HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
    Hurvitz, Sara
    Loi, Sherene
    O'Shaughnessy, Joyce
    Okines, Alicia
    Tolaney, Sara
    Sohn, Joo Hyuk
    Saura, Cristina
    Zhu, Xiaofu
    Cameron, David
    Bachelot, Thomas
    Hamilton, Erika
    Curigliano, Giuseppe
    Wolff, Antonio
    Harbeck, Nadia
    Masuda, Norikazu
    Vahdat, Linda
    Zaman, Khalil
    Valdes-Albini, Frances
    Block, Margaret
    Pluard, Timothy
    Tan, Tira
    Gawryletz, Chelsea
    Chan, Arlene
    Bedard, Philippe
    Yerushalmi, Rinat
    Xu, Binghe
    Tryfonidis, Konstantinos
    Schmitt, Michael
    Xie, Joan
    Borges, Virginia
    CANCER RESEARCH, 2024, 84 (09)
  • [33] COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATION
    Vondeling, G.
    Palaka, E.
    Livings, C.
    Naik, J.
    Sullivan, W.
    VALUE IN HEALTH, 2020, 23 : S433 - S434
  • [34] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [35] The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients with HER2+Metastatic Breast Cancer (TBCRC 062)
    Parsons, Heather
    Ruddy, Kathryn
    Morganti, Stefania
    Smith, Karen
    Attaya, Victoria
    Kallfelz, Eliza
    DeMeo, Michelle
    LaScala, Jamie
    Mertz, Shirley
    Pollastro, Teri
    Spears, Patricia
    Brufsky, Adam
    Dang, Chau
    Dent, Susan
    Elkhanany, Ahmed
    Gwin, WIlliam
    O'Sullivan, Ciara
    Miller, Kathy
    Nunnery, Sara
    Walsh, Elaine
    Storniolo, Anna Maria
    Tolaney, Sara
    Tayob, Nabihah
    Wolff, Antonio
    Winer, Eric
    Rimawi, Mothaffar
    Krop, Ian
    Lin, Nancy
    CANCER RESEARCH, 2024, 84 (09)
  • [36] Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
    Lin, Nancy U.
    Murthy, Rashmi K.
    Abramson, Vandana
    Anders, Carey
    Bachelot, Thomas
    Bedard, Philippe
    Borges, Virginia
    Cameron, David
    Cameron, David
    Carey, Lisa
    Chien, A. Jo
    Curigliano, Giuseppe
    DiGiovanna, Michael
    Gelmon, Karen
    Hortobagyi, Gabriel
    Hurvitz, Sara
    Krop, Ian
    Loi, Sherene
    Loibl, Sibylle
    Mueller, Volkmar
    Oliveira, Mafalda
    Paplomata, Elisavet
    Pegram, Mark
    Slamon, Dennis
    Zelnak, Amelia
    Ramos, Jorge
    Feng, Wentao
    Winer, Eric
    CANCER RESEARCH, 2022, 82 (04)
  • [37] The association of centromere amplification and response to trastuzumab in HER2+metastatic breast cancer
    Andrieu, Charlotte
    Al-Sultan, Dalal
    Ivers, Laura
    Pina, Jose Javier Berenguer
    Skrobo, Darko
    Ballot, Josephine
    Eustace, Alex J.
    Gullo, Giuseppe
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab plus trastuzumab in HER2+metastatic breast cancer patients previously treated with trastuzumab
    Baselga, J.
    Imadalou, K.
    Paton, V
    Gray, D.
    Swain, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 244S
  • [39] Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Iyengar, N. M.
    Smyth, L. M.
    Lake, D.
    Gucalp, A.
    Singh, J. C.
    Traina, T. A.
    Defusco, P.
    Dickler, M. N.
    Fornier, M. N.
    Goldfarb, S. B.
    Jhaveri, K.
    Modi, S.
    Troso-Sandoval, T.
    Jack, K.
    Ulaner, G.
    Jochelson, M.
    Baselga, J.
    Norton, L.
    Hudis, C. A.
    Dang, C. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Iyengar, N. M.
    Smyth, L.
    Lake, D.
    Gucalp, A.
    Singh, J.
    Traina, T. A.
    Defusco, P.
    Dickler, M. N.
    Fornier, M.
    Goldfarb, S.
    Jhaveri, K.
    Latif, A.
    Modi, S.
    Troso-Sandoval, T.
    Ulaner, G.
    Jochelson, M.
    Baselga, J.
    Norton, L.
    Hudis, C.
    Dang, C.
    ANNALS OF ONCOLOGY, 2016, 27
12345